Table 2.
miRNAs in therapeutic development.
| miRNA | Disease | Stage of clinical trial | Reference |
|---|---|---|---|
| miRNA replacement | |||
| let-7 | Lung cancer | Preclinical | [106] |
| miR-34 | Lung cancer, Prostate cancer | Preclinical | [107,108] |
| miR-29 | Cardiac fibrosis | Preclinical | [109] |
| miRNA antagonists | |||
| miR-122 | Hepatitis C virus | II | [110] |
| miR-208/499 | Chronic heart failure | Preclinical | [111] |
| miR-15/195 | Post-myocardial infarction remodeling | Preclinical | [112,113] |
| miR-206 | Amyotrophic lateral sclerosis | Preclinical | [114] |
| miR-451 | Myeloproliferative diseases | Preclinical | [115] |